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Abstract
Background: Multiple drug resistance (MDR) of cancer cells is the main reason of intrinsic or acquired insensitivity
to chemotherapy in many cancers. In this study we used ovarian cancer model of acquired drug resistance to study
development of MDR.
We have developed eight drug resistant cell lines from A2780 ovarian cancer cell line: two cell lines resistant to
each drug commonly used in ovarian cancer chemotherapy: cisplatin (CIS), paclitaxel (PAC), doxorubicin (DOX) and
topotecan (TOP). A chemosensitivity assay - MTT was performed to assess drug cross-resistance. Quantitative real-
time polymerase chain reaction and immunofluorescence were also performed to determine mRNA and protein
expression of genes/proteins involved in drug resistance (P-gp, BCRP, MRP1, MRP2, MVP). Flow cytometry was used
to determine the activity of drug transporters.
Results: We could observe cross-resistance between PAC- and DOX-resistant cell lines. Additionally, both PAC-
resistant cell lines were cross-resistant to TOP and both TOP-resistant cell lines were cross-resistant to DOX. We
observed two different mechanisms of resistance to TOP related to P-gp and BCRP expression and activity. P-gp
and BCRP were also involved in DOX resistance. Expression of MRP2 was increased in CIS-resistant cell lines and
increased MVP expression was observed in CIS-, PAC- and TOP-, but not in DOX-resistant cell lines.
Conclusions: Effectiveness of TOP and DOX in second line of chemotherapy in ovarian cancer can be limited
because of their cross-resistance to PAC. Moreover, cross-resistance of PAC-resistant cell line to CIS suggests that
such interaction between those drugs might also be probable in clinic.
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Background
One of the main reasons of low effectiveness of chemo-
therapy in cancer patients is drug resistance, which is in-
herent or, more often, acquired during treatment [1]. In
most cases drug resistance has features of Multiple Drug
Resistance (MDR). MDR is designated as an insensitivity
of cancer cells not only to previously used drug but also
to many other drugs with different chemical structure
and mechanism of action [2]. Majority of drugs used in
chemotherapy act as a cytotoxic agents then as cytostatic
ones. Although cancer cells develop various mechanisms
of resistance to cytotoxic drugs the first players impli-
cated in MDR are drug transporters from ABC family.
These proteins use energy from ATP hydrolysis for ac-
tive removing drugs from the cancer cells [3]. The most
important drug transporter is glycoprotein P (P-gp)
encoded by the multidrug resistance protein 1 gene
(MDR1, ABCB1) [4]. Expression of this protein was
noted in over 50 % of cancers with MDR phenotype and
it can be inherent or induced by chemotherapy [5]. Ap-
proximately 20 different cytotoxic drugs are substrates
to P-gp [6] and two of them - paclitaxel [7] and doxo-
rubicin [8] - are commonly used in chemotherapy of
many cancers. The second most important drug
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transporter is breast cancer resistant protein (BCRP)
encoded by ABCG2 gene, cloned for the first time from
breast cancer cell line MCF-7 [9]. The upregulated ex-
pression of BCRP was noted in many cancers including
breast [10] and ovarian [11] and is known to protect
cancer cells against mitoxantrone [10, 12] and topotecan
[11, 12]. Other important ABC transporters implicated
in MDR of cancers include MRP1 and MRP2 (MDR1-re-
lated protein 1 and MDR-related protein 2) encoded by
ABCC1 and ABCC2 genes, respectively [3, 13, 14]. Sub-
strates used by MRP1 are similar to those for P-gp with
the exception of taxanes [6]. Among many MRP2 sub-
strates the most important is cisplatin (CIS) and it is the
most frequently used antitumor agent in cancer therapy
[6, 12].
Another protein involved in MDR, but not belonging
to ABC drug transporters family, is MVP/LRP major
vault protein/lung resistance - related protein [15]. The
upregulation of MVP/LRP expression was noted in lung
cancer and was correlated with poor response to chemo-
therapy [16]. LRP expression increased after exposure to
CIS in non-small-cell lung cancer cells [17].
To better understand the mechanisms of drug resist-
ance development and cross-resistance to different cyto-
toxic drugs we used the ovarian cancer model, the most
lethal gynaecological cancer [18]. Ovarian cancer seems
to be an appropriate model to study mechanism of drug
resistance development because it is one of the most
treatable cancers at the beginning of the therapy [18].
Unfortunately, most of the patients with good response
to chemotherapy have recurrence with acquired MDR
[18, 19]. As a result, the second line of chemotherapy is
not curative [18].
The current research that improves the knowledge
about drug resistance development is based mainly on
drug sensitive and resistant cancer cell lines. However,
most studies are limited to only one or two resistant cell
lines. Therefore, we have developed eight drug resistant
cell lines from one parental A2780 ovarian cancer cell
line to make model of drug resistance more accurate
and effective. Cell lines used in our experiments were re-
sistant to cytotoxic drugs from the first line chemother-
apy regimen of ovarian cancer - paclitaxel (PAC) and
cisplatin (CIS) [20] - as well as to two drugs commonly
used in the second line of chemotherapy - doxorubicin
(DOX) and topotecan (TOP) [21, 22]. Such model en-
able us the comparison not only between the develop-
ment of drug resistance for drugs of the first and the
second line of chemotherapy, but also let us observe dif-
ferences in twin cell lines resistant to the same cytotoxic
drug.
Our study had four main goals: 1. To compare the
mechanism of drug resistance to cytotoxic agents used
in the first and the second line of ovarian cancer
chemotherapy. 2. To determine the expression of the
main genes in drug resistant cell lines. 3. To compare
the cross-resistance between cell lines resistant to inves-
tigated drugs. 4. To determine the differences and simi-




CIS, DOX, TOP, and PAC were obtained from Sigma
(St. Louis, MO). RPMI-1640 medium, fetal bovine
serum, antibiotic-antimycotic solution, and L-glutamine
were also purchased from Sigma (St. Louis, MO). A Cell
Proliferation Kit I (MTT) was purchased from Roche
Diagnostics GmbH (Mannheim, Germany). Goat anti-
MRP2 polyclonal (Ab) (H-17), rabbit anti-ABCG2
(BCRP) polyclonal Ab (H-70) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
monoclonal anti-P-glycoprotein Ab (C219) and mouse
monoclonal anti-MVP/LRP Ab (MVP 37) were obtained
from Alexis Biochemicals (Lörrach, Germany).
Cell lines and cell culture
The Human Ovarian Carcinoma Cell Line A2780 was
purchased from ATCC. A2780 sublines that were resist-
ant to CIS (A2780CR1, A2780CR2), PAC (A2780PR1,
A2780PR2), DOX (A2780DR1, A2780DR2), and TOP
(A2780TR1, A2780TR2) were generated by the exposure
of the A2780 cell line to incremental increases in the
concentrations of the relevant drugs. The final concen-
trations of each drug were 1000 ng/mL CIS, 1100 ng/mL
PAC, 100 ng/mL DOX, and 24 ng/mL TOP. These con-
centrations were based on the work of Dietel et al. in
1993 [23] and were twofold greater than the plasma con-
centrations of the respective drugs 2 h after intravenous
administration. All the cell lines were maintained as
monolayers in complete medium (MEM medium sup-
plemented with 10 % fetal bovine serum, 2 pM L-
glutamine, penicillin (100 units/mL), streptomycin (100
units/mL), and amphotericin B (25 μg/mL) at 37 °C in a
5 % CO2 atmosphere.
Drug sensitivity assay
The drug sensitivity of the A2780 cell line and the drug
resistant cell lines was confirmed by the MTT cell sur-
vival assay. Briefly, all cell lines were seeded at a density
of 5000 cells/well in 96-well plates. The cells were
allowed to grow for 48 h and subsequently treated with
fresh medium supplemented with or without increasing
concentrations of drugs and incubated for 72 h at 37 °C.
After 72 h of exposure, 10 μL of the MTT labeling re-
agent was added to the medium (the final concentration
of MTT was 0.5 mg/mL), and the cells were incubated
for additional 4 h. Following this process, 100 μL of
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solubilisation solution was added to each well. The ab-
sorbance of each sample was measured in a microplate
reader at 570 nm with a reference wavelength of
720 nm, according to the manufacturer’s protocol. The
negative control was conducted using cell-free culture
medium containing both the MTT reagent and solubil-
isation solution. The experiments were repeated three
times, and each concentration in a given experiment was
tested in duplicates. Cell viability was expressed as a per-
centage of the untreated control (means ± SEM).
Examination of gene expression by using Q-PCR
Changes in ABCB1, ABCC1, ABCC2, ABCG2 and LRP
genes expression in the A2780 and drug-resistant cell lines
were examined. Q-RT-PCR was conducted for four inde-
pendent experiments. RNA was isolated using the Gene
Matrix Universal RNA purification Kit (EURx Ltd.), as de-
scribed by the manufacturer. Reverse transcription was
performed using the M-MLV reverse transcriptase (Invi-
trogen) as described in the manufacturer’s protocol using
a thermal cycler (Veriti 96 well Thermal Cycler). 2 μg of
RNA was used to cDNA synthesis. Real-time PCR was
performed using the Applied Biosystems PCR System
(7900HT Fast Real-Time PCR System), Maxima SYBR
Green/ROX qPCR Master Mix (Fermentas) and
sequence-specific primers, as indicated in Table 1.
Glyceraldehyde-3-phosphate dehydrogenase (GADPH), β-
actin, hypoxanthine-guanine phosphoribosyltransferase 1
(HRPT1) and beta-2-microglobulin (β2M) served as the
normalizing genes (geometric mean) against which ex-
pression changes in the examined genes were compared.
Gene expression was analyzed using the relative quantifi-
cation (RQ) method. RQ estimates the difference in the
level of gene expression against a calibrator (A2780 drug
sensitive line) (RQ of the calibrator = 1). The A2780 cell
line was used as the calibrator. The analysis was con-
ducted employing the standard formula: RQ = (where for
the sample (drug-resistant line) − for the calibrator (drug
sensitive line)). The graphs were made using Sigma Plot.
For amplification, 12.5 μL of Maxima SYBR Green/
ROX qPCR Master Mix (Fermentas), 1 μL of each pri-
mer (Oligo, Warsaw, Poland) (Table 1), 9.5 μL of water,
and 1 μL of cDNA solution were mixed together. One
RNA sample of each preparation was processed without
RT-reaction to provide a negative control in subsequent
PCR. Sample amplification included a hot start (95 °C,
15 min) followed by 50 cycles of denaturation at 95 °C
for 15 s, annealing at 60 °C for 30 s, and extension at
72 °C for 30 s. After amplification, Melt Curve analysis
was performed to analyze product melting temperature.
The amplification products were also resolved by 3 %
agarose gel electrophoresis and visualized by ethidium
bromide staining.
Immunofluorescence analysis
The cells were cultured on microscopic glass slides and
grown to a near-confluent state. Afterwards, the cells
were fixed in 4 % PFA in PBS for 10 min at room
temperature, permeabilized in ice-cold acetone/metha-
nol (1:1) for 10 min at −20 °C, rinsed with PBS and
blocked in 3 % BSA for 45 min. Several primary anti-
bodies were used for detection including: MRP2 (1:50,
1 h/RT, goat polyclonal anti-human, clone H-17, Santa
Cruz Biotechnology), P-gp (1:100, 1 h/RT, mouse mono-
clonal anti-human, clone C219, Alexis Biochemicals),
BCRP (1:100, 1 h/RT, rabbit polyclonal anti-human,
clone H-70, Santa Cruz Biotechnology) and MVP/LRP
(1:50, 1 h/RT, mouse monoclonal anti-human, clone
MVP 37, Alexis Biochemicals) along with the corre-
sponding green dye labeled secondary antibody: anti-
goat, anti-rabbit, anti-mouse respectively (MFP488, don-
key anti-goat IgG, goat anti-mouse IgG, goat anti-rabbit
IgG; 1:200, 1 h/RT, MoBiTec). Afterwards, the cells were
washed three times with PBS and sealed with DAPI-
containing mounting medium. The cells were viewed
under a fluorescence microscope (Zeiss Axio-
Imager.Z1). The expression of MRP2, P-gp, BCRP and
MVP/LRP was analyzed using pseudo-colour representa-
tions of fluorescence intensity for DAPI at 365 nm exci-
tation and 420 nm emission wavelengths (blue) and for
MFP488 at 470 nm excitation and 525 nm emission
wavelengths (green).
Table 1 Oligonucleotide sequences used for Q-PCR analysis





ABCB1 TGACAGCTACAGCACGGAAG 00000265724 131 bp
TCTTCACCTCCAGGCTCAGT
ABCC1 GAGAGTTCCAAGGTGGATGC 00000399410 149 bp
AGGGCCCAAAGGTCTTGTAT
ABCC2 TACCAATCCAAGCCTCTACC 00000370449 104 bp
AGAATAGGGACAGGAACCAG
ABCG2 TTCGGCTTGCAACAACTATG 00000237612 128 bp
TCCAGACACACCACGGATAA
LRP TGAGGAGGTTCTGGATTTGG 00000357402 135 bp
TGCACTGTTACCAGCCACTC
GADPH GAAGGTGAAGGTCGGAGTCA 00000229239 199 bp
GACAAGCTTCCCGTTCTCAG
β-actin TCTGGCACCACACCTTCTAC 00000331789 169 bp
GATAGCACAGCCTGGATAGC
HRPT1 CTGAGGATTTGGAAAGGGTG 00000298556 156 bp
AATCCAGCAGGTCAGCAAAG
β2M CGCTACTCTCTCTTTCTGGC 00000558401 133 bp
ATGTCGGATGGATGAAACCC
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Flow cytometric analysis
To assess the efflux activity of P-gp, MRP2 and BCRP
in drug sensitive and resistant cell lines, we used the
fluorescent dye Rhodamine 123 (Rho123) as an index
of P-gp and MRP2 activity and Hoechst 33342
(H33342) as an index of BCRP activity. The cell sus-
pensions (1x106/ml) were incubated with 1 μg/ml
Rho123 or 1 μg/ml H33342 for 1 h at 37 °C in the
medium. Next, the cells were washed twice in ice
cold PBS with 500 μM verapamil (a known MDR in-
hibitor), and cellular uptake of Rho123 or H33342
was immediately analyzed using a FACSAria III (BD,
Warsaw, Poland) with the FCS Express Plus software
program. In each analysis, 10,000 events were re-
corded. The fluorescent emission was collected at
488 nm for Rho123 and at 375 nm for H33342.
Statistical analysis
The statistical analysis was performed using Microsoft
Excel software. The statistical significance of the differ-
ences was determined by applying the Student's t-test.
Results
Characteristics of A2780 and A2780 sublines
The CIS-resistant (A2780CR1, A2780CR2), PAC-
resistant (A2780PR1, A2780PR2), DOX-resistant
(A2780DR1, A2780DR2) and TOP-resistant (A2780TR1,
A2780TR2) variant sublines of the A2780 human ovar-
ian cancer cell line were all established by the stepwise
selection of A2780 cells cultured in growth media with
increasing drug concentrations. To determine the sensi-
tivity of the A2780 and drug-resistant A2780 sublines to
CIS, PAC, DOX, and TOP, cells were treated with differ-
ent concentrations of each drug for 72 h. The concentra-
tion- dependent effect of CIS on A2780 and the drug-
resistant cell lines was observed (Fig. 1a, Table 2). The
A2780DR1, A2780DR2, A2780TR1, A2780TR2 and
A2780PR1 cell lines were all sensitive to CIS treatment.
In contrast we observed an increased resistance to CIS
not only in both CIS-resistant cell lines (A2780CR1 and
A2780CR2) but also in A2780PR2 cell line in compari-
son with parental A2780 cell line.
We observed high cross-resistance between PAC-
and DOX-resistant cell lines (Fig. 1b and c, Table 2).
Also, Both PAC-resistant cell lines (A2780PR1 and
A2780PR2) demonstrated very high level of resistance
to DOX. Similarly, both DOX-resistant cell lines
(A2780DR1 and A2780DR2) were also resistant to
PAC. Among other cell lines we observed only
medium level of PAC cross-resistance in A2780TR2
cell line (Fig. 1b, Table 2). We also observed low level
of cross-resistance to DOX in A2780CR1 and
A2780TR1 cell lines and medium level of cross-
resistance in A2780TR2 cell line (Fig. 1c, Table 2).
The effect of TOP was also investigated. In A2780TR1
and A2780TR2 we observed high level of TOP resistance
(Fig. 1d, Table 2). We also observed cross-resistance to
TOP in both PAC-resistant cell lines. Furthermore,
A2780PR2 cell lines was more resistant to TOP than
A2780TR1 and A2780TR2 cell lines (Fig. 1d, Table 2).
Both TOP-resistant cell lines showed cross-resistance to
DOX (Fig. 1c, Table 2) and one A2780TR2 cell line
showed cross-resistance to PAC (Fig. 1b, Table 2).
Gene expression analysis in drug-resistant ovarian cancer
cell lines
To determine whether the development of drug-
resistance in the variant sublines of the A2780 parental
line is associated with increased expression of MDR-
associated genes, expression of the following mRNA
levels was assessed: MDR1, MRP1, MRP2, BCRP, and
LRP. We observed statistically significant increase of
MDR1 transcript level in both DOX-resistant cell lines
(P < 0.001), both PAC-resistant cell lines (P < 0.01 in
A2780PR1 cell line and P < 0.001 in A2780PR2 cell line)
and one TOP-resistant cell line A2780TR2 (P < 0.05)
(Fig. 2a). However, expression in A2780TR2 cell line was
much lower than in PAC- and DOX-resistant cell lines.
The transcript level of MRP1 was significantly decreased
in one CIS-resistant cell line (A2780CR1, P < 0.05) and
one TOP-resistant cell line (A2780TR1, P < 0.5) (Fig. 2b),
however, these changes were very low. MRP2 expression
increased in both CIS-resistant cell lines (P < 0.01 in
A2780CR1 cell line and P < 0.001 in A2780CR2 cell line)
(Fig. 2c). Both TOP-resistant cell lines were character-
ized by significantly increased BCRP transcript level (P <
0.001) (Fig. 2d). The LRP transcript level was signifi-
cantly higher in both CIS-resistant cell lines A2780CR1,
and A2780CR2 (P < 0.05 and P < 0.01, respectively), both
TOP-resistant cell lines (P < 0.01) and both PAC-
resistant cell lines A2780PR1 and A2780PR2 (P < 0.01
and P < 0.05, respectively) (Fig. 2e), however the increase
was not very high.
Immunofluorescence of MRP2, P-gp, BCRP and LRP in re-
sistant cell lines
To confirm the expression of investigated drug trans-
porters at the protein level, we used the immunofluores-
cence assay. The immunofluorescence analysis validated
the transcript expression results. We observed an in-
creased expression of MRP2 protein in the A2780 sub-
lines resistant to CIS (Fig. 3a). Similarly, the expression
of P-gp protein was observed in cell lines resistant to
DOX (A2780DR1 and A2780DR2) and PAC (A2780PR1
and A2780PR2) and at lower level in A2780TR2 cell line
resistant to TOP (Fig. 3b). We also observed expression
of BCRP protein in both TOP resistant cell lines
(A2780TR1 and A2780TR2) (Fig. 3c). The increase in
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MVP transcript level in CIS- and TOP-resistant cell
lines was very low, therefore we compared the protein
expression only between A2780 and both PAC-resistant
cell lines, where we could observe low increase in ex-
pression of MVP protein (Fig. 3d).
Analysis of drug transporters activity in drug resistant cell
lines
To determine whether expression of MRP2, P-gp and
BCRP correlates with their transporter activity or not
the fluorescence accumulation was investigated in drug
sensitive and resistant cell lines. The MRP2 and P-gp ac-
tivity was examined with the use of day Rho123 and ac-
tivity of BCRP with the use of day H33342, respectively.
We did not observe increased activity of MRP2 in
A780CR1 and A2780CR2 cell lines in comparison with
drug sensitive A2780 cell lines (Fig. 4a). Furthermore,
the accumulation of Rho123 was slightly higher in both
resistant cell lines (Fig. 5). In cell lines resistant to PAC
and DOX we observed much lower level of Rho123 ac-
cumulation than in drug sensitive cell line A2780
(Fig. 4b). A2780TR2 cell line was also characterized by
lower level of Rho123 accumulation than A2780 cell
lines, however, the differences were much lower than in
PAC- and DOX-resistant cell lines. The accumulation of
Rho123 in DOX-resistant cell lines A2780DR1 and
A2780DR2 was respectively 6.7 and 9.7 fold lower than
in drug sensitive A2780 cell line (Fig. 5). Similarly, the
accumulation in PAC-resistant cell lines A2780PR1 and
A2780PR2 was respectively 6.8 and 8.7 fold lower than
in drug sensitive A2780 cell line (Fig. 5). In A2780TR2
cell line we observed only 2.4 fold lower accumulation
of Rho123 than in A2780 cell line. In both TOP-resistant
cell lines (A2780TR1 and A2780TR2) we observed de-
creased accumulation of H33342 (Fig. 4c). The accumu-
lation of H33342 in A2780TR1 and A2780TR2 cell lines
was respectively 7.3 and 6.2 fold lower than in drug sen-
sitive A2780 cell line (Fig. 5).
Discussion
In the present study we investigated the development of
resistance to cytotoxic drugs after exposure the ovarian
Fig. 1 MTT analysis. MTT cell survival assay for A2780, A2780CR1, A2780CR2, A2780DR1, A2780DR2, A2780TR1, A2780TR2, A2780PR1 and A2780PR2
cell lines treated with or without increasing concentration of CIS (a), PAC (b), DOX (c), and TOP (d). The viability was expressed as a percent on
an untreated control (mean ± SEM)
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cancer cell line A2780 to cytotoxic drugs used in the
treatment of this cancer. The most important cyto-
toxic drug commonly used in ovarian cancer treat-
ment is CIS [18, 19]. It was previously described by
others that ovarian cancer cells can develop a special
metabolic mechanisms of resistance to cisplatin [24],
however simultaneous cross-resistance to another
drug was not observed in those cell lines. We could
observe increased resistance to CIS not only in both
CIS-resistant cell lines but also in A2780PR2 cell line
resistant to PAC. PAC is the second most important
drug in the first line chemotherapy of ovarian cancer
[19, 20]. Cross-resistance of PAC-resistant cell line to
CIS can suggest that in patients who developed resist-
ance to PAC, neither CIS can be an effective drug in
cancer treatment.
High level of cross-resistance between PAC- and
DOX-resistant cell lines is not surprising because cross-
resistance between cancer cells resistant to these drugs
has been documented by others [3, 6] and ours [25] pre-
viously. High level of cross-resistance between cell lines
resistant to these drugs suggests that DOX based
chemotherapy should not be recommended for patients
that developed resistance to PAC after the first line
chemotherapy.
Another drug that is commonly used in many cancers,
including second line chemotherapy in ovarian cancer, is
topotecan [18, 21]. Similar pattern of response to TOP
was observed in both TOP-resistant cell lines, and in
A2780PR2 cell line. A2780PR1 cell line also showed
TOP resistance, although at much lower level. High level
of resistance to TOP in PAC resistant cell line was previ-
ously observed by ours in another ovarian cancer cell
lines study [25]. Cross-resistance of PAC-resistant cell
lines to TOP raises the question whether TOP is a
proper drug for a second line of ovarian cancer chemo-
therapy or not.
The most important MDR protein is P-gp encoded
by MDR1 gene [4]. We observed very high level of
MDR1 transcript in both PAC- and both DOX- resist-
ant cell lines. In A2780TR2 cell line MDR1 transcript
level was also increased in comparison with the con-
trol cell line, however, at much lower level. Very simi-
lar results were obtained at protein level. Drug
transporter activity of P-gp determined by Rho 123
efflux was also higher in both PAC- and DOX- resist-
ant cell lines and in A2780TR2 cell line than in con-
trol. Increased expression and activity of P-gp in
DOX- and PAC- resistant cell lines is not surprising
because both drugs are well known substrates for P-
gp [3, 4, 7, 8, 26]. Similarly to the results of our pre-
vious studies [25] in current research we could ob-
serve very high correlation between MDR1 transcript
level, P-gp activity and IC50 in DOX- and PAC- re-
sistant cell lines. These results confirm that P-gp
plays most important role in the resistance to both
cytotoxic agents. Cross-resistance of A2780TR2 cell
line to DOX and PAC can also result from P-gp over-
expression in this cell line.
It is worth mentioning, that we also observed in-
creased MRP2 transcript level and protein expression in
both CIS-resistant cell lines. Expression of MRP2 in
CIS-resistant cell lines was also observed by others [27,
28]. Additionally, another cell line – A2780PR2 –
showed resistance to CIS, however, statistically signifi-
cant increase in MRP2 transcript level was not observed
in that cell line. In contrast to P-gp, that is considered as
a main player in PAC and DOX resistance, the MRP2
seems not to be the one and only important mechanism
in CIS resistance. It has been reported that
Table 2 Summary of cell line cross-resistance to drug treatment
IC50 (nM)
Cell line CIS PAC DOX TOP
A2780 1.83 3.37 6.34 10.8
(0.94–3.14) (2.84–3.76) (5.76–7.04) (5.76–20.0)
1 1 1 1
A2780CR1 7,49 3.43 41.5 37.3
(5.39–8.72) (3.09–3.93) (32.8–48.0) (31.7–43.7)
4.09 ↑ * 1.01 6.54 ↑ ** 3.45
A2780CR2 6.03 3.86 6.84 8.59
(5.12–7.10) (3.13–4.48) (6.07–8.02) (8.09–9.11)
3.29 ↑ * 1.15 1.08 0.79
A2780DR1 1.79 283 367 37.3
(1.64–1.96) (123–601) (253–496) (33.5–41.0)
0.98 84 ↑ ** 58 ↑ ** 3.45
A2780DR2 2.32 569 461 30,9
(0.86–3.06) (407–983) (353–596) (22.1–38.6)
1.27 169 ↑ ** 73 ↑ ** 2.86
A2780TR1 0.84 4.13 46.4 644
(0.36–1.40) (3.56–4.65) (34.6–68.6) (350–851)
0.46 1.22 7.3 ↑ * 59.6 ↑ **
A2780TR2 4.24 40.5 192 523
(2.91–4.95) (24.7–56.6) (59.4–252) (409–616)
2.31 12 ↑ ** 30 ↑ * 48.5 ↑ **
A2780PR1 3.41 491 419 61.4
(1.86–4.57) (457–534) (384–464) (49.9–70.3)
1.86 146 ↑ ** 66 ↑ ** 5.68 ↑ *
A2780PR2 15.5 4052 22,673 1398
(9.31–22.4) (3872–4452) (29,757–14,104) (880–1913)
8.46 ↑ ** 1202 ↑ ** 3476 ↑ ** 129 ↑ **
IC50 mean is indicated to each drug. The drug resistance in A2780 cell line
was assigned as 1. ↑ Underline values indicate multiplicities of resistance with
respect to A2780 cell line. *p < 0.01, **p < 0.001
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metallothioneins [29], glutathione [30] and glutathione
metabolizing enzymes [31], are also responsible for re-
sistance to this drug. Thus, cross-resistance of
A2780PR2 cell line can result from one of those mecha-
nisms. Although MRP2 transcript and protein expres-
sion were upregulated in both CIS-resistant cell lines,
the Rho123 accumulation was higher in both CIS-
resistant cell lines than in drug sensitive A2780 cell line.
This can result from the fact that Rho123 can also be
used as a substrate for other proteins from ABC trans-
porters family. Previously, we have reported downregula-
tion of ABCA3 in both CIS-resistant cell lines [32].
Thus, together with the upregulation of MRP2, the
downregulation of ABCA3 in these cell lines occurs and
Fig. 2 Gene expression analysis. Expression (Q-PCR) of MDR1 (a), MRP1 (b), MRP2 (c), BCRP (d), and LRP (e) genes. The figure presents relative
gene expression in resistant cell lines (grey bars) with respect to the A2780 cell line (white bars) assigned as 1. Values were considered significant
at *P < 0.05, **P < 0.01 and ***P < 0.001
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Fig. 3 Immunofluorescence analysis. Immunofluorescence visualization of: (a) MRP2 protein in A2780, A2780CR1 and A2780CR2 cell lines; (b) P-gp protein
in A2780, A2780DR1, A2780DR2, A2780PR1, A2780PR2 and A2780TR2 cell lines; (c) BCRP protein in A2780, A2780TR1 and A2780TR2 cell lines; (d) LRP/MVP
protein in A2780, A2780PR1 and A2780PR2 cell lines. All antigens were detected using respected primary antibodies and corresponding MFP488-
conjugated secondary antibodies (green). To visualize the cell nuclei, the cells were mounted with a DAPI-containing mounting medium (blue).
Objective x40
Fig. 4 Intracellular accumulation of Rho123 and H33342 in drug sensitive and resistant cell lines. The figure shows diagrams of the fluorescence
intensity, each consisting of the fluorescence intensity of the sensitive cell line and corresponding resistant cell lines. Sensitive cell lines are
indicated in black. Accumulation of Rho123 in cell lines with expression of MRP2 (a) and in cell lines with expression of P-gp (b). Accumulation of
H33342 in cell lines with expression of BCRP (c)
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can result in impaired transport and elevated accumula-
tion of Rho123 in CIS-resistant cell lines in comparison
with control.
The role of BCRP in resistance to TOP seems to be
well established [11, 33] and is confirmed by our re-
sults in the present and the previous study [25]. Rela-
tion between fluorescence intensity and transcript
levels observed in our experiment suggest that BCRP
plays an important and a leading role in TOP resist-
ance. However, we observed that both TOP-resistant
cell lines were also cross-resistant to DOX. As men-
tioned previously, the resistance of A2780TR2 cell
line to DOX and PAC can be related to P-gp expres-
sion, but in contrast to A2780TR2 increased expres-
sion of P-gp in A2780TR1 cell line was not observed.
Thus, it can be concluded that resistance to DOX in
A2780TR1 cell line is related to BCRP expression.
That kind of DOX resistance has been reported previ-
ously by others and is consistent with data that DOX
but not PAC is a substrate for BCRP [4, 6].
Among all our resistant cell lines we could observe two
different mechanisms of TOP resistance. Both TOP-
resistant cell lines showed “classical” mechanism of TOP-
resistance based on BCRP expression. It appears in oppos-
ition to both PAC-resistant cell lines where resistance to
TOP seems to be related to P-gp expression. It has been
reported that TOP is a substrate for P-gp [6] and expres-
sion of P-gp can protect cells against TOP [25, 34]. How-
ever, both DOX-resistant cell lines also showed very high
level of P-gp expression but were not resistant to TOP.
Similar observation was made by ours previously in an-
other DOX- and VIN- (vincristin) resistant ovarian cancer
cell lines. Although both cell lines expressed high level of
P-gp they were not resistant to TOP [25]. This suggests
that expression of P-gp can be important but not sufficient
for TOP resistance. P-gp mechanism of TOP resistance
requires further investigation.
Another question is about the reason of low level of
cross-resistance to DOX in A2780CR1 cell line and total
lack of DOX-resistance in A2780CR2 cell line. In
A2780CR1 cell line we could not observe any positive
expression of P-gp or BCRP. It has been previously re-
ported that MRP2 can also be related to DOX resistance
[6]. In our experiment the expression of MRP2 in
A2780CR1 cell line was slightly higher than in
A2780CR2 cell line and can be the reason of low level of
resistance to DOX in this cell line.
Another protein that is involved in MDR but does not
belong to ABC drug transporters family is LRP/MVP
[15]. In our experiment we have observed that LRP tran-
script level has risen in all examined CIS-, PAC- and
TOP-resistant cell lines, but not in DOX-resistant cell
lines. Increased expression in CIS-resistant cell lines is
consistent with data of Berger et al., who observed a cor-
relation between LRP expression and resistance to CIS
in NSCLC cell lines [17]. However, in contrast to other
study [35], LRP is evidently not involved in DOX-
resistance in our cell lines. Among all examined cell
lines the highest expression of LRP was observed in
PAC-resistant cell lines. The role of that protein in re-
sistance to PAC has been described by Tegze et al., who
observed a correlation between LRP expression and re-
sistance to PAC in breast cancer cell lines [36]. To our
knowledge, the role of LRP in TOP resistance has not
been described by others so far. Since the increase in
LRP expression in drug resistant cell lines was signifi-
cantly lower than the expression of ABC drug trans-
porters it can appear that LRP plays more of a
complementary and not the main role in MDR. This is
consistent with results of SiVa et al., who concluded that
Fig. 5 MRP2, P-gp and BCRP activity analysis. Mean fluorescence intensity (MIF) of Rho123 in A2780, A2780CR1 and A2780CR2 cells for MRP2
activity and in A2780DR1, A2780DR2, A2780PR1, A2780PR2 and A2780TR2 cells for P-gp activity. Mean fluorescence (MIF) of H33342 in A2780,
A2780TR1 and A2780TR2 cells for BCRP activity. The MFI was calculated automatically using the FACS Express Plus software program
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upregulation of LRP alone is not sufficient to influence
the drug resistance phenotype [37].
All drug resistant cell lines were developed from the
same A2780 drug sensitive cell line and, what is more,
all twin cell lines were resistant to the same cytotoxic
drug but we could still observe some particular differ-
ences. From two PAC-resistant cell line only one -
A2780PR2 - was cross-resistant to CIS and, similarly,
from both TOP-resistant cell lines only A2780TR2 re-
vealed increased level of P-gp and resistance to PAC.
Well-described standard response of cancer cells to
drugs results in increased expression of typical drug re-
sistance proteins. However, on the basis of our results
we can conclude that cancer cells are able to develop an
alternative and less specific pathways of response to drug
induced stress that leads to cytotoxic drugs cross-
resistance. The phenomenon of cross-resistance of can-
cer cells that has developed effective mechanisms against
different types of cytotoxic drugs can directly influence
the effectiveness of chemotherapy in ovarian cancer
patients.
Conclusions
In summary, our results confirm that expression of drug
transporters from ABC family is the main mechanism of
MDR in cancer cells. It is possible to predict drug cross-
resistance when the classical mechanism of MDR based
on P-gp expression is involved. We observed two mech-
anisms of TOP resistance: classical - based on BCRP ex-
pression in TOP-resistant cell lines and non classical -
related to P-gp expression in PAC-resistant cell lines. Ef-
fectives of TOP and DOX in the second line of chemo-
therapy in ovarian cancer can be limited because of their
cross-resistance to PAC. Moreover, LRP/MVP seems to
play a complementary role in resistance to cytotoxic
drugs. Cross-resistance of PAC-resistant cell line to CIS
suggests that such cross-resistance between those drugs
is also probable in clinic. Although the main mecha-
nisms of resistance in examined twin cell lines resistant
to the same cytostatic were similar, we could still ob-
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